Eledon Pharmaceuticals (ELDN) Form 3 Novus Therapeutics / Steven Perrin ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Perrin Steven

(Last) (First) (Middle)

C/O NOVUS THERAPEUTICS, INC.

19900 MACARTHUR BLVD., SUITE 550

(Street)

IRVINE CA 92612

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/14/2020

3. Issuer Name and Ticker or Trading Symbol
Novus Therapeutics, Inc. [ NVUS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	09/14/2030	Series X1 Convertible Preferred Stock(2)	7,856.409	500	D
Stock Option (Right to Buy)	(3)	01/28/2030	Series X1 Convertible Preferred Stock(2)	2,078.859	495	D
Stock Option (Right to Buy)	(3)	01/28/2030	Common Stock	48,896	0.495	D
Stock Option (Right to Buy)	(3)	01/28/2030	Series X1 Convertible Preferred Stock(2)	2,514.285	495	D
Stock Option (Right to Buy)	(3)	01/28/2030	Common Stock	56,719	0.495	D
Stock Option (Right to Buy)	(3)	09/07/2030	Series X1 Convertible Preferred Stock(2)	10,672.926	380.8	D
Stock Option (Right to Buy)	(3)	09/07/2030	Common Stock	240,767	0.3808	D
Stock Option (Right to Buy)	(4)	01/28/2030	Series X1 Convertible Preferred Stock(2)	432.257	495	D
Stock Option (Right to Buy)	(4)	01/28/2030	Common Stock	9,751	0.495	D
Stock Option (Right to Buy)	(4)	01/28/2030	Series X1 Convertible Preferred Stock(2)	656.165	495	D
Stock Option (Right to Buy)	(4)	01/28/2030	Common Stock	14,802	0.495	D

Explanation of Responses:

1. This option represents a right to purchase a total of 7,856.409 shares of the Issuer's Series X1 Convertible Preferred Stock, with 1,949.260 shares vesting in equal monthly installments over a period of one year from the grant date, and with the remaining 5,907.149 shares vesting over a period of two years from the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

2. Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.

3. The option vests in equal monthly installments over a period of four years from January 1, 2019, the vesting start date.

4. The option is fully vested.

Remarks:

President and Chief Scientific Officer Ex. 24 - Power of Attorney

	/s/ Ryan A. Murr, as attorney-in-fact for Steven Perrin	09/24/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.